A covalent antagonist for the human adenosine A2A receptor

• Published in: Purinergic signalling Vol. 13; no. 2; pp. 191 - 201
• Main Authors: Yang, Xue, Dong, Guo, Michiels, Thomas J.M., Lenselink, Eelke B., Heitman, Laura, Louvel, Julien, IJzerman, Ad P.
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.06.2017; Springer Nature B.V
• Subjects: Adenosine; Affinity; Amino acids; Benzene; Biomedical and Life Sciences; Biomedicine; Cancer Research; Crystallography; Human Physiology; Ligands; Lysine; Neurosciences; Original; Original Article; Pharmacology/Toxicology; Site-directed mutagenesis; Studies; X-ray crystallography; adenosine receptor; Covalent antagonist; A; Adenosine; G protein-coupled receptors; Radioligand binding
• ISSN: 1573-9538; 1573-9546
• DOI: 10.1007/s11302-016-9549-9

The structure of the human A 2A adenosine receptor has been elucidated by X-ray crystallography with a high affinity non-xanthine antagonist, ZM241385, bound to it. This template molecule served as a starting point for the incorporation of reactive moieties that cause the ligand to covalently bind to the receptor. In particular, we incorporated a fluorosulfonyl moiety onto ZM241385, which yielded LUF7445 (4-((3-((7-amino-2-(furan-2-yl)-[ 1 , 2 , 4 ]triazolo[1,5- a ][ 1 , 3 , 5 ]triazin-5-yl)amino)propyl)carbamoyl)benzene sulfonyl fluoride). In a radioligand binding assay, LUF7445 acted as a potent antagonist, with an apparent affinity for the hA 2A receptor in the nanomolar range. Its apparent affinity increased with longer incubation time, suggesting an increasing level of covalent binding over time. An in silico A 2A -structure-based docking model was used to study the binding mode of LUF7445. This led us to perform site-directed mutagenesis of the A 2A receptor to probe and validate the target lysine amino acid K153 for covalent binding. Meanwhile, a functional assay combined with wash-out experiments was set up to investigate the efficacy of covalent binding of LUF7445. All these experiments led us to conclude LUF7445 is a valuable molecular tool for further investigating covalent interactions at this receptor. It may also serve as a prototype for a therapeutic approach in which a covalent antagonist may be needed to counteract prolonged and persistent presence of the endogenous ligand adenosine.